We are live on ! Find out more
AST

Asterias Biotherapeutics
AST

Delisted

AST was delisted on the 7th of March, 2019.

66 hedge funds and large institutions have $18.3M invested in Asterias Biotherapeutics in 2016 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 18 increasing their positions, 10 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,775% more capital inflows, than outflows

Capital inflows: $11.9M | Capital outflows: $633K

220% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 5

80% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 10

20% more funds holding

Funds holding: 55 → 66 (+11)

5.09% more ownership

Funds ownership: 12.18% → 17.27% (+5.1%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
66
Holders Change
+11
Holders Change %
+20%
% of All Funds
1.76%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
16
Increased
18
Reduced
10
Closed
5
Calls
$52​K
Puts
–
Net Calls
+$52​K
Net Calls Change
+$134​K

AST Hedge Fund Activity: Q2 2016 in Review

66 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics (AST) for Q2 2016, worth a combined $18.3M — down 15% from $21.5M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new AST positions and 5 closed out — a net gain of 11 holders — while 18 added to existing stakes and 10 trimmed.

The largest buyer was Broadwood Capital, adding an estimated $7.44M. The largest seller was Fidelity Investments, cutting an estimated $485K.

  • 66 institutional investors held Asterias Biotherapeutics (AST) as of Q2 2016, up from 55 in Q1 2016.
  • Funds reported $18.3M of Asterias Biotherapeutics stock for Q2 2016, down 15% quarter-over-quarter.
  • 16 funds opened new Asterias Biotherapeutics positions in Q2 2016 and 5 closed out, a net change of +11 holders.
  • The largest Asterias Biotherapeutics buyer in Q2 2016 was Broadwood Capital, an estimated $7.44M added.
  • The largest Asterias Biotherapeutics seller in Q2 2016 was Fidelity Investments, an estimated $485K sold.

Based on aggregated 13F filings for Q2 2016.